Lyfegen partners EVERSANA on pricing, access resource
![EVERSANA and Lyfegen logos](/sites/default/files/styles/x_large/public/2025-01/Eversana_Lyfegen.jpg?itok=KlR9qi6T)
Two providers of intelligence on drug pricing and market access – Switzerland's Lyfegen and EVERSANA of the US – have joined forces to help pharma companies navigate an increasingly complex operating environment.
The alliance will pair EVERSANA's NAVLIN platform, which provides data and information on global pricing and market access, with Lyfegen's Public Drug Agreement Library, which is described as the largest digital repository of innovative pricing models and public drug pricing agreements sourced from around the world.
NAVLIN has price and access data from more than 100 countries and 50-plus health technology assessment (HTA) organisations, while Lyfegen's repository covers over 7,000 public pricing agreements.
The partners say that they are combining these resources with artificial intelligence (AI) analytics to help companies develop agreements tailored to specific market needs, streamline their decision-making, and adapt quickly to changing market trends and regulations.
For example, the new platform could help biopharma companies to prepare stronger HTA submissions on the clinical effectiveness, cost-effectiveness, and impact of a product on healthcare budgets, reducing the amount of time and meetings needed to complete submissions.
That could help to tackle rising drug costs and improve patient access to medicines globally, by allowing companies to address "inefficiencies, missed opportunities, and delays in delivering therapies to patients," according to the two companies.
"Together with Lyfegen, we can harness the power of AI to address one of the biggest challenges in healthcare – helping patients get timely access to life-saving medicines," said Jim Lang, chief executive of EVERSANA, which is pharmaphorum's parent company.
"By uniting our expertise and our global pricing innovations, we have the opportunity to deliver a solution that simplifies decision-making and improves access in healthcare systems worldwide," he added.
That sentiment was echoed by Girisha Fernando, CEO of Basel-based Lyfegen, who noted that the partnership is a "giant step" towards its mission of creating a more sustainable and equitable healthcare environment.
"By integrating EVERSANA's price and access data into our combined offerings, we're not just solving today's challenges – we're building a foundation for a smarter, more efficient drug access and pricing landscape."